View Older Stories View More Recent Stories
-
Quantum BioPharma (QNTM) Unaware of Any Material Change
-
Quantum BioPharma Unaware of Any Material Change
-
Quantum BioPharma Provides Corporate Update
-
Quantum BioPharma (QNTM) Continues to Diversify its Treasury with the Purchase of Another USD $1,000,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
-
Quantum BioPharma (QNTM) Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs
-
Quantum BioPharma (QNTM) Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzz
-
Quantum BioPharma (QNTM) Announces the Success of unbuzzd Clinical Trial
-
Quantum Biopharma in Court With Dr. Raza Bokhari on January 24, 2025 Seeking a Court Order to Declare Him to Be a Vexatious Litigant and Other Litigation Updates
-
Quantum BioPharma (QNTM) Now Trading on Upstream Under QNTM
-
Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM
-
Quantum BioPharma (QNTM) Approved to Dual List on Upstream
-
Quantum Biopharma Ltd. Approved to Dual List on Upstream
-
Quantum Biopharma Announces Closing of Second Tranche
-
Quantum BioPharma (QNTM) Acquires $1M of Bitcoin and Other Cryptos
-
Quantum Biopharma Diversifies Treasury With the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency
-
Quantum BioPharma (QNTM) Diversifies Treasury with the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies
-
Quantum Biopharma Announces Closing of First Tranche
-
Quantum BioPharma (QNTM) Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302
-
Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)
-
Quantum BioPharma (QNTM) Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million
-
Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million
-
Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against
-
Quantum BioPharma (QNTM) Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia
-
Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia
-
Quantum Biopharma (NASDAQ:QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, f
-
Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofi
-
Quantum BioPharma (QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700M
-
Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Mani
-
Quantum BioPharma (QNTM) Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South A
-
Quantum BioPharma Ltd. Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group across Puerto Rico, The Caribbean, and Parts of Central and South Ame
-
Quantum BioPharma (QNTM) Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group
-
Quantum BioPharma Ltd. Pharma Provides Update from Celly Nutrition Signing a Master Distribution Agreement with FUSION Distribution Group Across Puerto Rico, the Caribbean, and Parts of Central and So
-
Quantum Biopharma Provides Corporate Update
-
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Invesments and Kingswood US
-
Quantum BioPharma Closes Private Placement Offering
-
Quantum BioPharma (QNTM) Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
-
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
-
Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement and Completes Debt Settlements
-
Quantum Biopharma Announces Celly Nutrition Launches unbuzzd(TM) Grab-and-Go Stick Packs on Amazon.com so you can "own NOW and what’s NEXT"
-
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update
-
FSD Pharma (QNTM) Completes Name Change, 65:1 Share Consolidation, Ticker Change
-
FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation - Trading Under New Ticker Symbol "QNTM"
